		091-18235-ju
For Internal USeCEIVED	Submit 1 Original	
Only Sec FRONSAJAN 13 AM 7:24	and 9 Copies	OMB APPROVAL OMB Number: 3235-0504
SEC / TM securi	UNITED STATES (TIES AND EXCHANGE COMMISSIC Washington, D.C. 20549	DN Expires: August 31, 2010 Estimated average burden hours per response3.60 Mail Processing
Information Require	FORM 19b-4(e)	sting and Trading a New AN 122015
Derivative Securities Produc	ct Pursuant to Rule 19b-4(e) Under the	Securities Exchange AcLos 1934
READ AI	LL INSTRUCTIONS PRIOR TO COM	IPLETING FORM 404
Part I	Initial Listing Report	
1. Name of Self-Regulatory Organization Lis NASDAQ OMX BX, Inc. (traded pursu	uant to unlisted trading privileges)	
2. Type of Issuer of New Derivative Securitie Open End Management Investment (Company	aler, corporation. etc.): 15000053
3. Class of New Derivative Securities Produc Exchange Traded Fund	XII - Constant de la constant de la Constant de la constant	
4. Name of Underlying Instrument: Poliwogg Medical Breakthroughs Inc		
5. If Underlying Instrument is an Index, State Broad-based		13EG.
 Ticker Symbol(s) of New Derivative Secur SBIO 	rities Product:	
 Market or Markets Upon Which Securities Listed on: NASDAQ Stock Market LL 	LC, NYSE	es:
 Position Limits of New Derivative Securit Regular way trades settle on T + 3 (c) 	cash settled)	
 Position Limits of New Derivative Securit N/A 	ies Product (if applicable):	
Part II	Execution	
approved, or has duly delegated its an new derivative securities product acc standards.	governing body of the above-referenced S pproval to the undersigned for, the listing cording to its relevant trading rules, procee	and trading of the above-referenced
Name of Official Responsible for Form: Joan Conley		
Title: Secretary	\sim	
Telephone Number: 301-978-8735	$\sum (1)$	(
Manual Signature of Official Responsible for	Form:	W
Date: January 07, 2015		and a set of the set o
SEC 2449 (6-01)	<u>Istre</u>	and the second secon
	Pabl Avall	cuttinger JAN 1 2 2014